Duality Biologics Orally Presents Phase 1 Healthy Volunteer Data for First-in-Class BDCA2-Targeted ADC DB-2304 at Autumn Immunology Conference 2025

First Patient Dosed in Phase I/IIa Study of DualityBio’s BDCA2-Targeting ADC DB-2304 for Systemic Lupus Erythematosus

Fast Track Designation Granted for AVZO-1418/DB-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC

DualityBio DB-1324 HREC approval obtained and received TGA acknowledgment of the eCTN

Invitation Letter | 2025 DualityBio R&D Day

DualityBio’s ADAM9-Targeting ADC DB-1317 Receives FDA IND Clearance, Global Clinical Trials Initiated Simultaneously